12 results about "Vitamin receptor" patented technology

Disclosed herein are methods for treating metabolic syndrome in a subject using a vitamin D receptor agonist. A preferred vitamin D receptor agonist for the present invention is elocalcitol.

The invention relates to the technical field of feeds, in particular to a dietary dog food for recuperating gastrointestinal tracts of dogs and a preparation method thereof, and the dietary dog food comprises a basic nutritional agent, a gastric regurgitation preventing agent, a magnesium-zinc absorption promoting agent and a preservative. The modified sodium alginate forms gel in the stomach of the dog, sodium bicarbonate is decomposed to generate carbon dioxide gas to push the gel to float upwards to the cardia to form a shielding layer, and the modified cellulose releases calcium ions to promote crosslinking of the modified sodium alginate to form a more compact shielding layer so as to prevent backflow of contents in the stomach of the short-nose dog after the short-nose dog eats. The active form of vitamin D3 is combined with a vitamin D receptor in intestinal epithelial cells, gene expression of channels and ion transporters is up-regulated, and the absorption effect of dogs on magnesium and zinc in a high-calcium environment is promoted. The fructo-oligosaccharide enhances the signal transduction efficiency of the vitamin D3 by up-regulating the expression level of a vitamin D receptor, and further enhances the promotion effect of the vitamin D3 on magnesium and zinc absorption.

Proposed are a peptide activating vitamin D receptors and a cosmetic composition using the same.

Compositions and methods for treating or preventing obesity are provided. The compositions use compounds which act as vitamin D receptor agonists / activators (VDRA), preferably Vit D or calcitriol analogs or derivatives. The disclosed compositions can administered to a subject in need thereof, to treat on or more symptoms of obesity. The compounds can be used to promote a healthy body composition and to avoid the risks associated with overweight and / or obesity, such as cardiovascular disease cancers, urinary incontinence, diabetes and the like. The disclosed compositions can also be used prophylactically to treat animals that are overweight with a risk of becoming obese or animals that are at risk of becoming overweight and are on a high fat diet.

Compound having the following formula (I), wherein the groups R1 and R2 represent independently a functional group selected among a hydrogen and an aliphatic chain; R3 represents a functional group selected among a hydrogen and a methyl; - R5 represents a functional group selected among a hydrogen, a methyl and a methylene; - R6 represents a functional group selected among a hydrogen, methyl, methylene, ethyl and a ethylene; and - wherein the group Q is a carborane substituent having the following molecular formula : C2B10H11R7; wherein R7 represents a functional group selected among a hydrogen and an aliphatic chain; or a pharmaceutical acceptable derivative thereof, for use as a medicament.

Described herein are compounds, compositions, and methods for diagnosing and / or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.

A compound having the following formula (I): wherein groups R1 and R2 independently represent functional groups selected from hydrogen and aliphatic chains; R3 represents a functional group selected from hydrogen and methyl; R5 represents a functional group selected from hydrogen, methyl, and methylene; R6 represents a functional group selected from hydrogen, methyl, methylene, ethyl, and ethylene; and wherein group Q is a carborane substituent having the following molecular formula: C2B 10 H 11 R7; where R7 represents a functional group selected from hydrogen and aliphatic chains; or a pharmaceutically acceptable derivative thereof, which is used as a drug.

There is provided a compound of formula I or a pharmaceutically acceptable salt or solvate thereof, (Formula I) wherein W is a 5 or 6 membered heteroaryl group comprising at least one nitrogen atom; X1 is CO or O; X2, is NH or CH2; Y is O or CH2, and n is an integer of from 2 to 5. The compound is particularly useful for the treatment of proliferative diseases such as psoriasis or a cancer selected from the group consisting of leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, and breast cancer.

The invention relates to application of small chemical molecules in prevention or treatment of obesity and a composition containing the small chemical molecules, in particular to vitamin D, 25-hydroxyvitamin D or a vitamin D receptor agonist and application of analogues of the substances in preparation of products. Wherein the product is used for preventing and / or alleviating or treating obesity, overweight, or a symptom or state or trend or disease or condition caused by or associated with overweight or obesity in a mammal, or for reducing body weight.

Disclosed herein are methods of treating metabolic syndrome in a subject using a vitamin D receptor agonist. The preferred vitamin D receptor agonist of the present invention is ellocalciferol.

The use of vitamin D and a vitamin D receptor inhibitor in the preparation of a drug for regulating the activation of primordial follicles. Vitamin D can inhibit the activation of primordial follicles, and a vitamin D receptor inhibitor promotes the activation of primordial follicles, and thus same can be used as a drug for regulating the activation of primordial follicles in patients with premature ovarian insufficiency, and has good application prospects.

The invention discloses application of a leptin gene in preparation of a product for auxiliary identification of premature delivery of newborns of Han population, and belongs to the technical field of biomedicine. Risk assessment is carried out on relevance of polymorphism and clinical phenotypes of neonatal leptin genes, leptin receptor genes, irisin precursor FNDC5 genes and vitamin D receptor genes and premature delivery occurrence, risk factors of premature delivery are analyzed by adopting multi-factor logistic regression, and results show that premature delivery occurrence is based on genetic susceptibility. The result caused by the combined action of various exogenous factors shows that the polymorphic site genotype GG of the leptin gene rs7799039 of the neonates of the Han population is related to premature delivery; the age of the mother is increased, and the preplacenta may be a risk factor of premature delivery. The invention provides a new strategy for preventing premature delivery of neonates of Han population.